Gyre Therapeutics (GYRE) Asset Writedowns and Impairment (2015 - 2022)
Gyre Therapeutics (GYRE) posted quarterly Asset Writedowns and Impairment of $200000.0 for Q1 2022, up 49.25% quarter-over-quarter from $134000.0 in Q2 2015.
Gyre Therapeutics (GYRE) Asset Writedowns and Impairment (2015 - 2022) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Asset Writedowns and Impairment for 2 consecutive years, with $200000.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Asset Writedowns and Impairment changed N/A year-over-year to $200000.0; the TTM figure through Dec 2022 stood at $200000.0 (changed N/A YoY), while the FY2022 annual figure was $200000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment rose to $200000.0 in Q1 2022 per GYRE's latest filing, from $134000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $200000.0 in Q1 2022 and bottomed at $200000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 200,000.00 |
| Mar 31, 2022 | 200,000.00 |
| Jun 30, 2015 | 134,000.00 |
| Jun 30, 2015 | 134,000.00 |